Affibody Medical Investor Relations
Categories:
Navigation:
Regulatory
November 16, 2021
Affibody enters agreement with ACELYRIN for the development and commercialization of izokibep at a total deal value of USD 305 million plus royalties
Solna, Sweden, November 16, 2021. Affibody AB today announced a partnership agreement with ACELYRIN, INC., (“ACELYRIN”) to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple...
Read more
March 15, 2021
Annual Report 2021
Annual Report 2021, March 15, 2022